vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and TruBridge, Inc. (TBRG). Click either name above to swap in a different company.
TruBridge, Inc. is the larger business by last-quarter revenue ($87.8M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 0.0%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $8.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 2.2%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
TruBridge, Inc. provides end-to-end revenue cycle management, health IT solutions, and administrative support services primarily for rural and community healthcare providers across the United States, helping clients optimize operational efficiency and improve financial performance.
PBYI vs TBRG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $87.8M |
| Net Profit | — | $-4.3M |
| Gross Margin | 69.3% | 54.3% |
| Operating Margin | 22.7% | 5.7% |
| Net Margin | — | -4.9% |
| Revenue YoY | 27.7% | 0.0% |
| Net Profit YoY | — | 22.8% |
| EPS (diluted) | $0.26 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | $87.8M | ||
| Q3 25 | $54.5M | $86.1M | ||
| Q2 25 | $52.4M | $85.7M | ||
| Q1 25 | $46.0M | $87.2M | ||
| Q4 24 | $59.1M | $87.8M | ||
| Q3 24 | $80.5M | $84.7M | ||
| Q2 24 | $47.1M | $85.6M | ||
| Q1 24 | $43.8M | $84.1M |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $8.8M | $5.6M | ||
| Q2 25 | $5.9M | $2.6M | ||
| Q1 25 | $3.0M | $459.0K | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $20.3M | $-9.1M | ||
| Q2 24 | $-4.5M | $-4.4M | ||
| Q1 24 | $-4.8M | $-1.9M |
| Q4 25 | 69.3% | 54.3% | ||
| Q3 25 | 77.7% | 51.2% | ||
| Q2 25 | 76.5% | 51.9% | ||
| Q1 25 | 77.1% | 54.7% | ||
| Q4 24 | 76.4% | 52.8% | ||
| Q3 24 | 63.9% | 50.0% | ||
| Q2 24 | 77.4% | 49.4% | ||
| Q1 24 | 75.5% | 50.4% |
| Q4 25 | 22.7% | 5.7% | ||
| Q3 25 | 17.6% | 4.7% | ||
| Q2 25 | 12.7% | 4.2% | ||
| Q1 25 | 8.7% | 9.4% | ||
| Q4 24 | 22.6% | 7.2% | ||
| Q3 24 | 27.4% | 3.3% | ||
| Q2 24 | -4.6% | -2.5% | ||
| Q1 24 | -5.3% | -0.7% |
| Q4 25 | — | -4.9% | ||
| Q3 25 | 16.2% | 6.5% | ||
| Q2 25 | 11.2% | 3.0% | ||
| Q1 25 | 6.5% | 0.5% | ||
| Q4 24 | — | -6.3% | ||
| Q3 24 | 25.2% | -10.8% | ||
| Q2 24 | -9.6% | -5.1% | ||
| Q1 24 | -11.0% | -2.2% |
| Q4 25 | $0.26 | $-0.28 | ||
| Q3 25 | $0.17 | $0.37 | ||
| Q2 25 | $0.12 | $0.17 | ||
| Q1 25 | $0.06 | $0.03 | ||
| Q4 24 | $0.40 | $-0.38 | ||
| Q3 24 | $0.41 | $-0.61 | ||
| Q2 24 | $-0.09 | $-0.29 | ||
| Q1 24 | $-0.10 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $24.9M |
| Total DebtLower is stronger | $22.7M | $164.6M |
| Stockholders' EquityBook value | $130.3M | $178.0M |
| Total Assets | $216.3M | $402.5M |
| Debt / EquityLower = less leverage | 0.17× | 0.93× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | $24.9M | ||
| Q3 25 | $94.4M | $19.9M | ||
| Q2 25 | $96.0M | $12.3M | ||
| Q1 25 | $93.2M | $10.1M | ||
| Q4 24 | $101.0M | $12.3M | ||
| Q3 24 | $96.7M | $8.6M | ||
| Q2 24 | $96.8M | $7.7M | ||
| Q1 24 | $107.2M | $4.1M |
| Q4 25 | $22.7M | $164.6M | ||
| Q3 25 | $34.0M | $164.3M | ||
| Q2 25 | $45.3M | $166.1M | ||
| Q1 25 | $56.7M | $167.8M | ||
| Q4 24 | $68.0M | $171.6M | ||
| Q3 24 | $79.3M | $176.3M | ||
| Q2 24 | $90.7M | $180.0M | ||
| Q1 24 | $102.0M | $184.8M |
| Q4 25 | $130.3M | $178.0M | ||
| Q3 25 | $115.3M | $180.4M | ||
| Q2 25 | $104.7M | $173.2M | ||
| Q1 25 | $97.1M | $168.5M | ||
| Q4 24 | $92.1M | $167.1M | ||
| Q3 24 | $71.1M | $172.0M | ||
| Q2 24 | $48.5M | $179.8M | ||
| Q1 24 | $51.0M | $182.7M |
| Q4 25 | $216.3M | $402.5M | ||
| Q3 25 | $202.9M | $399.4M | ||
| Q2 25 | $194.9M | $390.2M | ||
| Q1 25 | $196.2M | $388.8M | ||
| Q4 24 | $213.3M | $395.8M | ||
| Q3 24 | $220.7M | $401.5M | ||
| Q2 24 | $205.0M | $412.3M | ||
| Q1 24 | $214.1M | $416.4M |
| Q4 25 | 0.17× | 0.93× | ||
| Q3 25 | 0.30× | 0.91× | ||
| Q2 25 | 0.43× | 0.96× | ||
| Q1 25 | 0.58× | 1.00× | ||
| Q4 24 | 0.74× | 1.03× | ||
| Q3 24 | 1.12× | 1.02× | ||
| Q2 24 | 1.87× | 1.00× | ||
| Q1 24 | 2.00× | 1.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $8.9M |
| Free Cash FlowOCF − Capex | $14.4M | $8.4M |
| FCF MarginFCF / Revenue | 19.1% | 9.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | $35.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $8.9M | ||
| Q3 25 | $9.7M | $13.6M | ||
| Q2 25 | $14.1M | $8.8M | ||
| Q1 25 | $3.6M | $5.8M | ||
| Q4 24 | $15.6M | $9.3M | ||
| Q3 24 | $11.0M | $10.1M | ||
| Q2 24 | $1.0M | $13.8M | ||
| Q1 24 | $11.2M | $-2.0M |
| Q4 25 | $14.4M | $8.4M | ||
| Q3 25 | $9.7M | $13.5M | ||
| Q2 25 | $14.1M | $8.2M | ||
| Q1 25 | $3.6M | $5.4M | ||
| Q4 24 | $15.6M | $8.9M | ||
| Q3 24 | $11.0M | $9.1M | ||
| Q2 24 | $1.0M | $13.6M | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | 19.1% | 9.5% | ||
| Q3 25 | 17.7% | 15.7% | ||
| Q2 25 | 26.8% | 9.6% | ||
| Q1 25 | 7.7% | 6.2% | ||
| Q4 24 | 26.4% | 10.2% | ||
| Q3 24 | 13.7% | 10.8% | ||
| Q2 24 | 2.1% | 15.9% | ||
| Q1 24 | — | -2.6% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.1% | 0.4% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.0% | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 2.43× | ||
| Q2 25 | 2.41× | 3.39× | ||
| Q1 25 | 1.21× | 12.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PBYI
Segment breakdown not available.
TBRG
| Financial Health Segment | $56.7M | 65% |
| Patient Care Segment | $31.1M | 35% |
